Egg Yolk Oil - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The egg yolk oil market size is projected to be USD 328.96 million in 2025, USD 344.71 million in 2026, and reach USD 448.68 million by 2031, growing at a CAGR of 5.41% from 2026 to 2031. This report is Segmented by Product Type (Hen Egg Yolk Oil and Specialty Egg Yolk Oils), Form (Powder and Liquid), Nature (Conventional and Organic), Distribution Channel (Industrial, Foodservice, and Retail), and Geography (North America, Europe, Asia-Pacific, South America, and Middle East and Africa). The Market Forecasts are Provided in Terms of Value (USD).

Global Egg Yolk Oil Market Trends and Insights

Growth in clean-label personal care ingredients

The shift toward ingredient transparency in personal care is now embedded in formulator strategy as brands reformulate away from synthetic emollients under tightening substance restrictions. EU Cosmetics Regulation (EC) No. 1223/2009 absorbed new amendments in early 2025, which added nanomaterial prohibitions and restricted several conventional cosmetic actives, effective February 2025, with full market withdrawal deadlines through November 2025, that redirected attention toward naturally derived lipids such as natural egg oil for cosmetics, which carry no REACH restriction concerns. A peer-reviewed overview in Frontiers in Nutrition confirmed that egg yolk lecithin forms bilayer vesicles structurally equivalent to human cell membranes, enabling dermal penetration of active compounds that synthetic alternatives cannot replicate, a functional credential that positions the ingredient as a regulatory-safe bioactive emollient in a single formulation component. The compliance advantage of egg-derived lipids is a structural tailwind embedded in a regulatory trajectory rather than a temporary consumer preference cycle.

Expansion of egg yolk phospholipid-based nutraceutical delivery

The driver frequently underweighted in market commentary is that pharmaceutical-grade egg yolk phospholipid demand is increasingly pulled by liposomal and LNP delivery formats, which require the high phosphatidylcholine purity that only egg-derived phospholipids reliably supply at injectable grades. A January 2026 review in Food Science (Liu et al., 47(2): 386-397) formally documented that egg yolk lecithin outperforms soy lecithin in liposome formation quality, neuroprotective bioactivity, and hepatoprotective function, strengthening the science basis for egg-sourced materials in clinical nutrition and advanced supplement formats. VAV Life Sciences' pharmaceutical-grade egg phospholipids, produced at its EU cGMP-certified facility, carry GRAS approval for preterm infant formula, a dual-channel qualification spanning pharmaceutical and functional food that soy-derived alternatives have not matched. As nutraceutical brands integrate liposomal delivery to justify premium pricing, egg yolk phospholipid procurement in this channel will increasingly follow pharmaceutical-grade specification requirements rather than commodity standards.

Raw egg price volatility

The structural vulnerability of the egg yolk oil supply chain became explicit during the 2024-2025 HPAI cycle. A wave of HPAI outbreaks from mid-October 2024 through early March 2025 resulted in the depopulation of 50.7 million egg-laying hens in the United States, according to the USDA Economic Research Service, coinciding with peak holiday baking demand and contributing to both wholesale and retail egg prices surging to all-time highs. The U.S. Bureau of Labor Statistics Consumer Price Index recorded a 53% year-over-year increase in retail egg prices from January 2024 to January 2025, with the national average reaching USD 6.23 per dozen in March 2025, a direct feedstock cost shock for processors. The Federal Reserve Bank of St. Louis documented that over 168 million egg-laying hens have been killed since 2022, and that egg demand is characteristically inelastic, meaning processors cannot easily pass input cost increases to price-sensitive industrial buyers. A less-discussed embedded restraint is that large concentrated production complexes, the same scale that enables cost-efficient processing, create systemic HPAI vulnerability, since a single positive detection triggers full complex depopulation under USDA biosecurity protocols, a structural risk unlikely to resolve within the forecast horizon.

Other drivers and restraints analyzed in the detailed report include:

• Advancements in egg yolk oil extraction technologies
• Increasing demand for natural hair and scalp care solutions
• Egg-allergen labelling and product-approval requirements

Segment Analysis

Hen egg yolk oil held an 86.51% share in 2025, a position anchored by the global scale of hen egg production, established supply chains, and decades of regulatory acceptance across pharmaceutical, food, and cosmetic applications. Kewpie Corporation's EGG YOLK OIL PL-30S, containing approximately 30% phospholipids and conforming to Japanese Standards of Quasi-Drug Ingredients, illustrates hen-derived material's formulation versatility across emulsifier, emollient, and nutritional phospholipid functions in both food and cosmetic channels.

Specialty Egg Yolk Oils from duck, quail, and other avian sources are forecast to grow at 6.46% CAGR through 2031, the fastest in the segment, propelled by differentiated phospholipid profiles commanding premium cosmetic positioning, and by the FDA's January 2025 allergen guidance clarification that paradoxically created labelling clarity supporting commercialization of non-hen specialty oils. The 2026 Food Science review (Liu et al.) confirmed that structural variability between avian-source lecithin phospholipid compositions has meaningful implications for liposome performance, signaling that multi-species blending strategies for pharmaceutical and cosmetic grade differentiation will expand over the forecast period.

Liquid egg yolk oil maintained 73.62% of value share in 2025, reflecting established processing infrastructure, ease of handling, and direct formulation compatibility in topical, injectable, and liquid nutraceutical applications. Its established use in these formats supports stable demand from pharmaceutical, cosmetic, and nutraceutical manufacturers. Lipoid GmbH's pharmaceutical-grade egg phospholipid offerings, including LIPOID E 80 (80% phosphatidylcholine) and LIPOID E PC S (≥96% phosphatidylcholine), are manufactured in liquid or pasty form, underscoring the dominant role of liquid in high-value pharmaceutical channels.

Powder is the fastest-growing form at 7.11% CAGR through 2031, driven by innovation in spray-drying and microencapsulation that enables incorporation into solid supplement formats with improved oxidative stability, shelf life, and transportation efficiency. This format also supports broader use in tablets, capsules, functional foods, and dry blends. A 2024 Chinese-language study in China Oils and Fats optimized encapsulation parameters for egg yolk lipid powdered oil, confirming that supercritical CO₂-extracted lipids encapsulated with a maltodextrin, modified corn starch, and whey protein wall system achieved optimal encapsulation efficiency, a formulation now informing industrial-scale powder manufacturing in China's export-oriented ingredient sector.

Complete Report Scope:

• Product Type
  • Hen Egg Yolk Oil
  • Specialty Egg Yolk Oils (Duck, Quail and Others)
• Form
  • Powder
  • Liquid
• Nature
  • Conventional
  • Organic
• Distribution Channel
  • Industrial
    • Food and Beverage
    • Cosmetics and Personal Care
    • Dietary Supplements
    • Pharmaceuticals
    • Other Industrial Applications
  • Foodservice
  • Retail
• Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • Middle East and Africa
    • United Arab Emirates
    • South Africa
    • Saudi Arabia
    • Turkey
    • Rest of Middle East and Africa

Geography Analysis

Asia-Pacific held 39.9% of the Egg yolk oil market share in 2025, making it the largest regional market. The region combines large-scale egg production with increasingly advanced processing and formulation capabilities. China supports raw material availability at competitive cost, while Japan contributes proprietary extraction knowledge and pharmaceutical-grade phospholipid manufacturing. Kewpie's egg ingredient portfolio and quasi-drug-grade product range demonstrate the region's ability to serve food and cosmetic applications. India is also building a position in pharmaceutical-grade supply through VAV Life Sciences' certified manufacturing capabilities. These conditions give Asia-Pacific a strong base in both high-volume oil and specialized phospholipid production.

North America is forecast to grow at a 6.9% CAGR through 2031, the fastest among the regions considered. Demand comes from established supplement consumption, clean beauty adoption, and clear compliance pathways for experienced manufacturers. Balchem reported FY2025 net sales of USD 1.03 billion, up 8.8% year over year, reflecting demand for encapsulated lipid and choline-based ingredient platforms across food, supplement, and pharmaceutical customers. The region also faced a sharp raw material shock after HPAI-related flock losses. U.S. retail egg prices reached USD 6.23 per dozen in March 2025 after 50.7 million laying hens were depopulated, according to the United States Department of Agriculture (USDA). This pressure is encouraging processors to assess supply diversification, including Canadian and Mexican sources.

Europe is a mature but technically demanding part of the Egg yolk oil market. Germany is a key supply center because Lipoid operates from the region and serves pharmaceutical-grade phospholipid demand. EU cosmetic restrictions and REACH documentation requirements favor certified producers with traceable supply chains. Regulation 2025/651 authorized lecithins, identified as E 322, as carriers in glazing agents for cassava and certain fresh fruits, creating additional food-grade use in the European Union. South America has future demand potential through Brazil's supplement sector and Argentina's agricultural processing base. The Middle East and Africa remain smaller markets, but personal care demand can provide a path for specialized haircare and skincare products.

List of Companies Covered in this Report:

• Lipoid GmbH
• Kewpie Corporation
• Ecovatec Solutions Inc.
• VAV Life Sciences Private Limited
• Hunan Health-Guard Bio-Tech Inc.
• Natural Sourcing LLC
• Bizen Chemical Co., Ltd.
• Jiangxi Global Natural Spice Co., Ltd.
• PERSSEH Company
• BOC Sciences
• Go Natural Pakistan
• Ariul Essential
• Shaanxi GTL Biotech Co., Ltd.
• Tedukuri Shizenshoku Tomonokai
• Parchem Fine & Specialty Chemicals
• Balchem Corporation
• Sanovo Technology Group
• NutraScience Labs
• Pancosma S.A.
• Bioseutica S.L.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support